School of Medicine and Surgery, University of Milan-Bicocca, Monza, Italy; Department of Surgery, San Gerardo Hospital, Monza, Italy.
Department of General Surgery and Transplantation, Ca'Granda Niguarda Hospital, Milan, Italy.
Eur J Surg Oncol. 2018 Oct;44(10):1580-1587. doi: 10.1016/j.ejso.2018.05.018. Epub 2018 May 22.
The extent of liver resection for the optimal treatment of hepatocellular carcinoma (HCC) is debated. The purpose of this study was to compare the impact of anatomic resection (AR) vs. parenchyma-sparing resection (PSR) on disease recurrence and patient survival.
We retrospectively analyzed patients with HCC who underwent liver resection from January 2001 to August 2015. Patients receiving AR or PSR were compared by a propensity score analysis (PSA) (caliper = 0.1). The primary outcomes were disease-free survival (DFS) and overall survival (OS) rates, and assessed by the Kaplan-Meier method.
455 consecutive patients were evaluated. After PSA 354 patient were studied (177 pairs for each group). The median follow-up time was 28.2 months. The median OS was 47.5 months (95% CI: 30.0-65.9) for AR and 56.5 months (95% CI 33.2-79.6) for PSR (p = 0.169). The median DFS was 29.2 months (95% CI 17.6-40.8) for AR and 24.8 months (95% CI: 15.2-34.2) for PSR (p = 0.337). The multivariate regression model showed that cirrhosis (HR 2.85, 95% CI: 1.53-5.32; p = 0.001), BCLC grade B (HR 4.15, 95% CI: 1.33-12.95; p = 0.014), microvascular invasion (HR 1.55, 95% CI: 1.03-2.31; p = 0.033), presence of satellitosis (HR 1.94, 95% CI: 1.25-3.01; p = 0.003), severe complications (HR 6.09, 95% CI: 2.26-16.40; p > 0.001) were independently associated with poor long-term oncologic outcomes.
The extent of resection did not significantly affect overall and disease-free survival while tumor characteristics and underlying liver function appeared significant determinants.
对于肝细胞癌(HCC)的最佳治疗,肝切除术的范围仍存在争议。本研究旨在比较解剖性肝切除术(AR)与保残肝切除术(PSR)对疾病复发和患者生存的影响。
我们回顾性分析了 2001 年 1 月至 2015 年 8 月接受肝切除术的 HCC 患者。通过倾向评分分析(PSA)(卡尺=0.1)比较接受 AR 或 PSR 的患者。主要观察终点为无病生存率(DFS)和总生存率(OS),并采用 Kaplan-Meier 法评估。
共评估了 455 例连续患者。经 PSA 后,354 例患者被纳入研究(每组 177 对)。中位随访时间为 28.2 个月。AR 组的中位 OS 为 47.5 个月(95%CI:30.0-65.9),PSR 组为 56.5 个月(95%CI:33.2-79.6)(p=0.169)。AR 组的中位 DFS 为 29.2 个月(95%CI:17.6-40.8),PSR 组为 24.8 个月(95%CI:15.2-34.2)(p=0.337)。多变量回归模型显示肝硬化(HR 2.85,95%CI:1.53-5.32;p=0.001)、BCLC 分级 B(HR 4.15,95%CI:1.33-12.95;p=0.014)、微血管侵犯(HR 1.55,95%CI:1.03-2.31;p=0.033)、卫星灶存在(HR 1.94,95%CI:1.25-3.01;p=0.003)、严重并发症(HR 6.09,95%CI:2.26-16.40;p>0.001)与长期肿瘤预后不良独立相关。
切除范围对总体和无病生存率无显著影响,而肿瘤特征和潜在肝功能是重要的决定因素。